BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP
875 results:

  • 1. [Drastic changes in the treatment of metastatic prostate cancer].
    Thellenberg Karlsson C; Ståhl O
    Lakartidningen; 2024 Apr; 121():. PubMed ID: 38651316
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: experience from a clinical diagnostic center from greater Shanghai area.
    Wu Z; Zhang Q; Jin Y; Zhang X; Chen Y; Yang C; Tang X; Jiang H; Wang X; Zhou X; Yu F; Wang B; Guan M
    BMC Cancer; 2024 Apr; 24(1):411. PubMed ID: 38566028
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. cancer trend and radiotherapy utilization at a tertiary academic hospital in Malaysia.
    Gan DEH; Bustam AZ
    J Cancer Res Ther; 2024 Jan; 20(1):358-362. PubMed ID: 38554346
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. [Molecular testing of prostate cancer: timing, methods and consequences].
    von Amsberg G; Paulsen FO
    Aktuelle Urol; 2024 Apr; 55(2):123-133. PubMed ID: 38537659
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of prostate cancer.
    Kalampokis N; Zabaftis C; Spinos T; Karavitakis M; Leotsakos I; Katafigiotis I; van der Poel H; Grivas N; Mitropoulos D
    Curr Oncol; 2024 Feb; 31(3):1162-1169. PubMed ID: 38534919
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management.
    Shi Y; Wang H; Golijanin B; Amin A; Lee J; Sikov M; Hyams E; Pareek G; Carneiro BA; Mega AE; Lagos GG; Wang L; Wang Z; Cheng L
    Urol Oncol; 2024 May; 42(5):144-154. PubMed ID: 38485644
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Abrogation of KLF5 sensitizes
    Zhang Z; Liu Y; Xu Y; Xu Z; Jia J; Jin Y; Wang W; Liu L
    Acta Biochim Biophys Sin (Shanghai); 2024 Apr; 56(4):576-585. PubMed ID: 38433576
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Precision Medicine in Castration-Resistant prostate cancer: Advances, Challenges, and the Landscape of PARPi Therapy-A Narrative Review.
    Dimitrov G; Mangaldzhiev R; Slavov C; Popov E
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396858
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Contemporary Systemic Therapy Intensification for prostate cancer: A Review for General Practitioners in Oncology.
    Batra A; Glick D; Valdes M
    Curr Oncol; 2024 Feb; 31(2):1047-1062. PubMed ID: 38392072
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway.
    Mahlow J; Barry M; Albertson DJ; Jo YJ; Balatico M; Seasor T; Gebrael G; Kumar SA; Sayegh N; Tripathi N; Agarwal N; Swami U; Sirohi D
    Hum Pathol; 2024 Feb; 144():28-33. PubMed ID: 38278448
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Microsatellite Instability Is Insufficiently Used as a Biomarker for Lynch Syndrome Testing in Clinical Practice.
    Papadopoulou E; Rigas G; Fountzilas E; Boutis A; Giassas S; Mitsimponas N; Daliani D; Ziogas DC; Liontos M; Ramfidis V; Christophilakis C; Matthaios D; Floros T; Florou-Chatzigiannidou C; Agiannitopoulos K; Meintani A; Tsantikidi A; Katseli A; Potska K; Tsaousis G; Metaxa-Mariatou V; Nasioulas G
    JCO Precis Oncol; 2024 Jan; 8():e2300332. PubMed ID: 38271656
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Germline DNA Damage Response Gene Mutations in Localized prostate cancer.
    Januskevicius T; Vaicekauskaite I; Sabaliauskaite R; Matulevicius A; Vezelis A; Ulys A; Jarmalaite S; Jankevicius F
    Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38256334
    [No Abstract]    [Full Text] [Related]  

  • 13. Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant prostate cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.
    van der Zande K; Tutuhatunewa-Louhanepessy RD; Hamberg P; Ras S; de Feijter JM; Dezentjé VO; Broeks A; Cornelissen S; Beeker A; van der Noort V; Zwart W; Bergman AM
    Clin Genitourin Cancer; 2024 Apr; 22(2):445-453.e1. PubMed ID: 38246830
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Predictive and prognostic biomarkers in urological tumours.
    Cimadamore A; Franzese C; Di Loreto C; Blanca A; Lopez-Beltran A; Crestani A; Giannarini G; Tan PH; Carneiro BA; El-Deiry WS; Montironi R; Cheng L
    Pathology; 2024 Mar; 56(2):228-238. PubMed ID: 38199927
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Whole-exome sequencing of Nigerian benign prostatic hyperplasia reveals increased alterations in apoptotic pathways.
    White JA; Kaninjing ET; Adeniji KA; Jibrin P; Obafunwa JO; Ogo CN; Mohammed F; Popoola A; Fatiregun OA; Oluwole OP; Thorpe RJ; Karanam B; Elhussin I; Ambs S; Tang W; Davis M; Polak P; Campbell MJ; Brignole KR; Rotimi SO; Dean-Colomb W; Odedina FT; Yates C
    Prostate; 2024 Apr; 84(5):460-472. PubMed ID: 38192023
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. A novel targeted NGS panel identifies numerous homologous recombination deficiency (HRD)-associated gene mutations in addition to known BRCA mutations.
    Vogel A; Haupts A; Kloth M; Roth W; Hartmann N
    Diagn Pathol; 2024 Jan; 19(1):9. PubMed ID: 38184614
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Simvastatin Enhances the Radiosensitivity of Androgen-independent prostate cancer Cells
    Oka D; Sekine Y; Tsuji Y; Nakayama H; Miyazawa Y; Arai S; Koike H; Suzuki K
    Anticancer Res; 2024 Jan; 44(1):93-98. PubMed ID: 38159995
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Prevalence of germline brca1/2 pathogenic variants in Japanese patients treated with castration-resistant prostate cancer and efficacy of CRPC treatment in real-world clinical practice.
    Maekawa S; Takata R; Sekiguchi K; Kagabu M; Toyoshima M; Tamada S; Takahashi K; Ikarashi D; Matsuura T; Kato R; Kato Y; Kanehira M; Sugimura J; Abe T; Baba T; Obara W
    Jpn J Clin Oncol; 2024 Apr; 54(4):489-497. PubMed ID: 38157885
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Combining Novel Hormonal Therapies with a Poly (ADP-Ribose) Polymerase Inhibitor for Metastatic Castration-Resistant prostate cancer: Emerging Evidence.
    Yang J; Xiong X; Zheng W; Liao X; Xu H; Yang L; Wei Q
    Curr Oncol; 2023 Dec; 30(12):10311-10324. PubMed ID: 38132385
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Pilot Trial of Streamlined Genetic Education and Traceback Genetic Testing in prostate cancer Survivors.
    Schwartz MD; Peshkin BN; Isaacs C; Grisham C; Holmes NJ; Sorgen LJ; Collins S; Dawson N; McGuire C; Okobi T; Newell K; Kolla KA; Weinstein V
    J Natl Compr Canc Netw; 2023 Dec; 21(12):1261-1268.e14. PubMed ID: 38081141
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 44.